Patents by Inventor Junko Oki

Junko Oki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for screening a test substance for activating a receptor associated with FGF 21 activity
    Patent number: 8697369
    Abstract: Using betaKlotho or a substance that increases or inhibits betaKlotho activity as an agent for controlling the activity of FGF21 mediated by an FGF receptor, the present invention provides a pharmaceutical composition comprising such betaKlotho or such substance as an active ingredient, particularly, a pharmaceutical composition for anti-metabolic syndrome, and further particularly, a pharmaceutical composition for therapeutic or preventive use associated with the control of blood glucose level. In addition, the present invention provides a screening system for each of a substance that enhances or suppresses betaKlotho activity, an FGF21-like active substance, and a betaKlotho-like active substance, which uses a cell system that has expressed an FGF receptor and/or betaKlotho on the surface thereof.
    Type: Grant
    Filed: April 7, 2008
    Date of Patent: April 15, 2014
    Assignee: National Institute of Advanced Industrial Science and Technology
    Inventors: Masashi Suzuki, Toru Imamura, Yuriko Uehara, Kaori Motomura, Junko Oki, Syuichi Oka, Masahiro Asada, Akiko Kuramochi, Miho Kimura
  • METHOD FOR ACTIVATING RECEPTOR BY COFACTOR AND METHOD FOR UTILIZING LIGAND ACTIVITY
    Publication number: 20100184665
    Abstract: Using betaKlotho or a substance that increases or inhibits betaKlotho activity as an agent for controlling the activity of FGF21 mediated by an FGF receptor, the present invention provides a pharmaceutical composition comprising such betaKlotho or such substance as an active ingredient, particularly, a pharmaceutical composition for anti-metabolic syndrome, and further particularly, a pharmaceutical composition for therapeutic or preventive use associated with the control of blood glucose level. In addition, the present invention provides a screening system for each of a substance that enhances or suppresses betaKlotho activity, an FGF21-like active substance, and a betaKlotho-like active substance, which uses a cell system that has expressed an FGF receptor and/or betaKlotho on the surface thereof.
    Type: Application
    Filed: April 7, 2008
    Publication date: July 22, 2010
    Inventors: Masashi Suzuki, Toru Imamura, Yuriko Uehara, Kaori Motomura, Junko Oki, Syuichi Oka, Masahiro Asada, Akiko Kuramochi, Miho Kimura